Pharmacokinetics of the combination tablet of buprenorphine and naloxone.

[1]  S. Walsh,et al.  The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic. , 2003, Drug and alcohol dependence.

[2]  D. Leiderman,et al.  Safety and health policy considerations related to the use of buprenorphine/naloxone as an office-based treatment for opiate dependence. , 2003, Drug and alcohol dependence.

[3]  Reese T. Jones,et al.  Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine. , 2000, Drug and alcohol dependence.

[4]  T. Kosten,et al.  Thrice-weekly versus daily buprenorphine maintenance , 2000, Biological Psychiatry.

[5]  L. Amass,et al.  Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet. , 2000, Drug and alcohol dependence.

[6]  Gary J. Badger,et al.  Buprenorphine dosing every 1, 2, or 3 days in opioid-dependent patients , 1999, Psychopharmacology.

[7]  K. Schuh,et al.  Pharmacokinetic comparison of the buprenorphine sublingual liquid and tablet. , 1999, Drug and alcohol dependence.

[8]  R. Jones,et al.  Buprenorphine Pharmacokinetics: Relative Bioavailability of Sublingual Tablet and Liquid Formulations , 1999, Journal of clinical pharmacology.

[9]  Reese T. Jones,et al.  Dose proportionality of 4, 8, 16 and 32 mg sublingual buprenorphine solutions , 1999 .

[10]  K. Chiba,et al.  Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[11]  W. Ling,et al.  Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. , 1998, Addiction.

[12]  P. Fudala,et al.  Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts. , 1998, Drug and alcohol dependence.

[13]  P. Jacob,et al.  Subnanogram-concentration measurement of buprenorphine in human plasma by electron-capture capillary gas chromatography: application to pharmacokinetics of sublingual buprenorphine. , 1997, Clinical chemistry.

[14]  D J Crouch,et al.  Determination of buprenorphine in human plasma by gas chromatography-positive ion chemical ionization mass spectrometry and liquid chromatography-tandem mass spectrometry. , 1997, Journal of analytical toxicology.

[15]  F. Berthou,et al.  Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes. , 1997, Life sciences.

[16]  H. Kotaki,et al.  Kinetics of respiratory depression in rats induced by buprenorphine and its metabolite, norbuprenorphine. , 1997, The Journal of pharmacology and experimental therapeutics.

[17]  Reese T. Jones,et al.  Bioavailability of Sublingual Buprenorphine , 1997, Journal of clinical pharmacology.

[18]  E. Cone,et al.  Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. , 1996, Journal of analytical toxicology.

[19]  W. Bickel,et al.  Buprenorphine treatment of opioid dependence: A review. , 1995 .

[20]  H. Kotaki,et al.  Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling. , 1995, The Journal of pharmacology and experimental therapeutics.

[21]  K. Preston,et al.  Clinical pharmacology of buprenorphine: Ceiling effects at high doses , 1994, Clinical pharmacology and therapeutics.

[22]  J. Jaffe,et al.  A controlled trial of buprenorphine treatment for opioid dependence. , 1992, JAMA.

[23]  J. Sear,et al.  Buprenorphine disposition in patients with renal impairment: single and continuous dosing, with special reference to metabolites. , 1990, British journal of anaesthesia.

[24]  K. Foley,et al.  Sublingual absorption of selected opioid analgesics , 1988, Clinical pharmacology and therapeutics.

[25]  E. Cone,et al.  The metabolism and excretion of buprenorphine in humans. , 1984, Drug metabolism and disposition: the biological fate of chemicals.

[26]  R. Moore,et al.  Sublingual buprenorphine used postoperatively: ten hour plasma drug concentration analysis. , 1982, British journal of clinical pharmacology.

[27]  G. Woody,et al.  CLINICAL PHARMACOLOGY OF NARCOTIC ANTAGONISTS * , 1978, Annals of the New York Academy of Sciences.

[28]  D. Jasinski,et al.  Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. , 1978, Archives of general psychiatry.

[29]  J. Hempstead,et al.  Pharmacokinetics of Naloxone in Rats and in Man: Basis for Its Potency and Short Duration of Action , 1976, Anesthesiology.

[30]  L. Hellman,et al.  Disposition of naloxone-7,8,3H in normal and narcotic-dependent men. , 1973, The Journal of pharmacology and experimental therapeutics.

[31]  L. Amass,et al.  Thrice-weekly supervised dosing with the combination buprenorphine-naloxone tablet is preferred to daily supervised dosing by opioid-dependent humans. , 2001, Drug and alcohol dependence.

[32]  Reese T. Jones,et al.  Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers , 1999, Psychopharmacology.

[33]  G. Badger,et al.  Alternate-day dosing during buprenorphine treatment of opioid dependence. , 1994, Life sciences.

[34]  R. Moore,et al.  Single-dose comparison of buprenorphine 0.3 and 0.6 mg i.v. given after operation: clinical effects and plasma concentration. , 1982, British journal of anaesthesia.

[35]  B. Berkowitz.  The Relationship of Pharmacokinetics to Pharmacological Activity: Morphine, Methadone and Naloxone , 1976, Clinical pharmacokinetics.